What Is Thymosin Alpha-1? Science & Evidence

TL;DR: Thymosin Alpha-1 (thymalfasin, trade name Zadaxin) is a synthetic 28-amino acid peptide originally isolated from bovine thymus, studied extensively for its role as an immune modulator. Acting through Toll-like receptor (TLR) signaling, dendritic cell activation, and Th1 polarization, it is one of the most clinically studied thymic peptides in existence, with regulatory approval as a drug in more than 35 countries for hepatitis B and C, and ongoing investigation in sepsis, cancer adjuvant contexts, and infectious disease. It is not approved by the U.S. FDA for any therapeutic use, and in 2023 the FDA specifically restricted its compounding.

Research-Use Disclaimer: This article is for educational and research reference purposes only. Thymosin Alpha-1 (thymalfasin) is a research compound in the United States context. Where approved as a prescription drug in other jurisdictions, it is available only under licensed medical supervision. This content does not constitute medical advice, does not recommend or endorse human self-administration of any compound, and does not describe personal-use protocols. All study findings described below refer to published literature. For adults 21+ with a research interest only.

What Is Thymosin Alpha-1? Definition, Origins, and Regulatory Context

Thymosin Alpha-1, abbreviated Tα1, also written thymosin alpha-1, thymalfasin, or by its trade name Zadaxin, is a synthetic 28-amino acid polypeptide whose sequence was originally isolated from thymosin fraction 5, a bovine thymus extract. The peptide corresponds to amino acids 1–28 of prothymosin alpha, a protein found in abundance in the thymic microenvironment where T-cell maturation occurs.

The compound’s development was led by SciClone Pharmaceuticals, which commercialized it under the trade name Zadaxin. As documented in a 2002 review by Billich in Current Opinion in Investigational Drugs, thymalfasin was approved and launched in Argentina, China, Peru, the Philippines, Singapore, Thailand, Mexico, Venezuela, and multiple other countries for the treatment of chronic hepatitis B virus (HBV) infection, with approval subsequently expanded to include hepatitis C virus (HCV) infection in several markets; the compound also entered Phase III trials in the United States in combination with PEGylated interferon-alpha and was being investigated for non-small cell lung cancer, hepatocellular carcinoma, AIDS, and malignant melanoma (PMID: 12090542).

A note on naming confusion: despite sharing “thymosin” in its name, Thymosin Alpha-1 is entirely unrelated to TB-500 or Thymosin beta-4. The two peptides differ in sequence, structure, target biology, mechanism, and clinical history. See the TB-500 compound profile for details on the beta-4 family.

What Are the Documented Mechanisms of Thymosin Alpha-1?

Thymosin Alpha-1 does not operate through a single receptor or pathway. The published research characterizes it as a pleiotropic immune modulator acting at multiple points along innate and adaptive immune signaling. The core mechanistic pathways documented in peer-reviewed literature are summarized below.

1. Toll-Like Receptor Signaling and Dendritic Cell Activation

The most mechanistically specific work on Thymosin Alpha-1 identifies Toll-like receptor (TLR) signaling as a primary pathway. A 2004 study by Romani et al. in Blood, investigating Tα1’s antifungal immune-resistance activity, found that thymosin alpha-1 induces functional maturation and interleukin-12 production by dendritic cells through the p38 MAPK/NF-κB-dependent pathway, acting via the MyD88-dependent signaling pathway involving distinct Toll-like receptors; in vivo, it activated Th1-dependent antifungal immunity, accelerated myeloid cell recovery, and protected highly susceptible transplant-recipient mice from aspergillosis (PMID: 14982877).

The TLR specificity was further refined in a 2007 study by Bozza et al. in International Immunology, which demonstrated that thymosin alpha-1 protected susceptible and resistant mice from murine cytomegalovirus infection by activating plasmacytoid dendritic cells via the TLR9/MyD88-dependent viral recognition pathway, leading to activation of IFN regulatory factor 7 and promotion of the IFN-α/IFN-γ effector pathway (PMID: 17804687). Together, these two studies document Tα1’s engagement of both myeloid DCs (via TLR2 and related pathways) and plasmacytoid DCs (via TLR9), providing a mechanistic framework for its broad immunostimulatory profile across pathogen classes.

2. T-Cell Maturation and Th1 Cytokine Polarization

The original biological rationale for thymosin research was the role of the thymus in T-cell development. A comprehensive 2016 review by King and Tuthill in Vitamins and Hormones synthesizes the mechanistic literature: Tα1 has a pleiotropic mechanism of action affecting multiple immune cell subsets involved in immune suppression; it acts through Toll-like receptors in both myeloid and plasmacytoid dendritic cells, leading to activation and stimulation of signaling pathways and initiation of production of immune-related cytokines; due to these immunostimulating effects, the compound has been studied for utility in immune suppression related to aging, infection, and cancer (PMID: 27450734).

At the T-cell level, the documented effects include stimulation of T-helper cell differentiation, upregulation of Th1 cytokines (interferon-gamma, interleukin-2), and augmentation of natural killer cell-mediated cytotoxicity, as summarized in the 2004 review by Chien and Liaw in Expert Review of Anti-Infective Therapy, which noted that in vitro studies have shown that Tα1 can influence T-cell production and maturation, stimulate production of Th1 cytokines such as interferon-gamma and interleukin-2, and activate natural killer cell-mediated cytotoxicity (PMID: 15482167).

What Does the Clinical Research Show? An Evidence-Tiered Review

Thymosin Alpha-1 has one of the larger published human clinical trial datasets of any compound in the thymic peptide category. The following summarizes each major clinical research area with primary source citations, ordered from strongest to least complete evidence as of 2026.

Chronic Hepatitis B, Randomized Controlled Trial Data

Hepatitis B is the indication with the deepest clinical evidence base for Tα1. A 2001 review by Ancell, Phipps, and Young in the American Journal of Health-System Pharmacy, a comprehensive summary of the trial record at that time, documents that in four randomized and controlled clinical trials enrolling 195 patients with chronic hepatitis B, one randomized controlled trial found HBV DNA clearance in 40.6% and 25.6% of patients treated with Tα1 for 6 and 12 months respectively, compared with 9.4% of untreated controls; an open-label trial found HBV DNA clearance in 53% of patients at six months (PMID: 11381492). The review also characterized the adverse effect profile as favorable, primarily local injection-site irritation, across the trials examined.

A 2015 editorial by Wu, Jia, and You in Expert Opinion on Biological Therapy, reviewing studies through the entecavir-combination era, confirmed that Tα1 monotherapy is effective in suppressing viral replication compared with untreated controls or conventional interferon in chronic hepatitis B, with most combination therapy studies of Tα1 plus lamivudine or IFN-α showing better effects on HBV DNA suppression and HBeAg seroconversion, and clinical studies of Tα1 combined with entecavir for HBV-cirrhosis ongoing at time of publication (PMID: 25640173).

Chronic Hepatitis C, Mixed Results

The hepatitis C evidence is more nuanced. According to a 2010 review by Ciancio and Rizzetto in Annals of the New York Academy of Sciences, a large Phase III randomized European study in HCV patients who were non-responders to PEG-interferon with ribavirin demonstrated that thymalfasin did not improve the rate of sustained virologic responses, but in patients who completed therapy, thymalfasin significantly diminished the relapse rate; smaller combination studies had previously suggested improved ALT normalization rates (71% versus 35% for combination versus IFN-α alone) and HCV RNA clearance (65% versus 29%) (PMID: 20536462). The mixed hepatitis C data illustrates the difficulty of generalizing immunomodulator effects across heterogeneous patient populations, a consistent theme in the Tα1 clinical literature.

Sepsis, Emerging Clinical Evidence

Sepsis represents a more recent clinical research context for Tα1, grounded in its documented ability to restore immune function in immunosuppressed states. A 2018 review by Pei, Guan, and Wu in Expert Opinion on Biological Therapy summarizes the clinical sepsis literature: in previous studies, single or combined treatment with Tα1 reduced the mortality rate of sepsis, improved the expression of HLA-DR on monocytes (a marker of restored immune function), and diminished the incidence of secondary infection; the authors note, however, that sepsis is a heterogeneous clinical syndrome and present studies cannot focus specifically on immunosuppressive individuals, suggesting that future trials selecting septic patients with immunosuppression would more clearly reveal Tα1’s efficacy (PMID: 30063866).

Cancer Adjuvant and COVID-19 Research Contexts

Tα1’s documented ability to restore immune function in immunosuppressed individuals has driven investigation as a cancer adjuvant and, more recently, as a potential prophylactic approach in high-risk populations during respiratory infection outbreaks. A 2021 paper by Bersanelli et al. in Future Oncology described the rationale for the PROTHYMOS study, a Phase II randomized trial evaluating Tα1 as prophylaxis for severe COVID-19 in cancer patients undergoing active treatment, stating that the immune stimulating properties of Tα1 provide a rationale for prophylactic use in this frail population, with the hypothesis that an effective prophylactic approach would have immediate clinical relevance given the lack of curative options at time of writing (PMID: 33538178).

The broadest synthesis of the clinical safety and efficacy record to date is a 2024 narrative review by Dinetz and Lee in Alternative Therapies in Health and Medicine, examining over 30 trials across more than 11, 000 human subjects. The review found that Tα1 has demonstrated consistent evidence of safety and tolerability across clinical trials in COVID-19, infectious diseases, autoimmune disorders, and cancer; the authors characterize the compound as a well-tolerated immune modulator and note that the 2023 FDA restriction on compounding appears to conflict with the body of existing trial evidence (PMID: 38308608). Note: this review was published in a journal with a less rigorous peer-review process than specialty clinical journals; researchers should weigh it accordingly and consult primary trial publications for specific indication-level evidence.

What Is Thymosin Alpha-1’s Evidence Tier? An Honest Assessment

Thymosin Alpha-1 occupies a distinct position in the research peptide landscape because of its substantial human clinical trial record, a characteristic that separates it from most compounds in this category, where Tier 2 (animal models only) is the ceiling. The following table documents the evidence landscape as of 2026.

The critical nuance to state accurately: Thymosin Alpha-1 is a genuinely atypical compound in this research landscape because it has cleared Phase III human trials for at least one indication (hepatitis B) and is a licensed pharmaceutical in dozens of countries. However, it is equally important to note that (a) those approvals do not apply to the U.S. context, where FDA restrictions on compounding reflect current regulatory status; (b) the evidence is indication-specific, results in hepatitis B do not generalize to other hypothetical uses without independent clinical trial support; and (c) “approved elsewhere” is a regulatory fact, not an endorsement of any particular research use. This article is a reference document, not a protocol guide.

What Is Thymosin Alpha-1’s Regulatory Status?

International Approvals (Zadaxin / Thymalfasin)

Thymalfasin under the trade name Zadaxin received pharmaceutical approvals in multiple countries for the treatment of chronic HBV and HCV infection beginning in the 1990s. Documented approval countries include China, the Philippines, Argentina, Peru, Singapore, Thailand, Mexico, Venezuela, Malta, Sri Lanka, Brunei, India, Laos, South Korea (as an influenza vaccine adjuvant and HBV/HCV treatment), and others, as documented in public regulatory filings and the 2002 Billich review cited above. Researchers should consult current regulatory authority databases directly for up-to-date status in any given jurisdiction.

FDA (United States)

Thymosin Alpha-1 has never received FDA approval for any therapeutic indication in the United States, despite completing Phase III trials for hepatitis C in the U.S. market. In 2023, the FDA placed thymalfasin on its list of bulk drug substances that may not be used in compounding under Section 503A, alongside 21 other peptide compounds. This restriction means it cannot be legally compounded and dispensed by U.S. pharmacies. Researchers should consult current FDA guidance directly for the most up-to-date classification and any IND or trial-related exemptions.

WADA (World Anti-Doping Agency)

Thymosin Alpha-1 is not individually named in the WADA Prohibited List’s specific compound enumerations as of the 2025–2026 lists. However, WADA’s Prohibited List uses broad category language under Section S4 (Hormone and Metabolic Modulators) and Section S0 (Non-Approved Substances, covering any pharmacological substance not approved by a regulatory authority for human therapeutic use in any jurisdiction). Athletes competing under WADA-compliant anti-doping programs should consult the current WADA Prohibited List, their national anti-doping organization, or use the WADA Global DRO tool to confirm status before any potential use. The research framing of this article does not apply to competitive sports contexts.

How Does Thymosin Alpha-1 Differ from Other Thymosin-Named Peptides?

The naming convention causes significant confusion. “Thymosin” describes a broad class of biologically active peptides originally isolated from thymic extracts, they are not a structurally or functionally unified family. The major thymosin-named peptides in research literature differ fundamentally:

• Thymosin Alpha-1 (Tα1 / thymalfasin), 28 amino acids; thymic origin; TLR/DC/Th1 immune modulator; clinical trials in infectious disease and cancer; approved as Zadaxin in 35+ countries.
• Thymosin Beta-4 (Tβ4) / TB-500, 43 amino acids (full protein) or synthetic fragment; ubiquitous in mammalian cells; G-actin sequestration mechanism; tissue repair research context; detailed in the TB-500 compound profile.
• Thymosin Fraction 5, the crude bovine thymus extract from which Tα1 was originally isolated; a mixture of peptides, not a single defined compound.

These distinctions matter for literature interpretation: studies on Tβ4 do not support claims about Tα1 and vice versa. The shared “thymosin” label is historical nomenclature, not a functional classifier.

Frequently Asked Questions About Thymosin Alpha-1

What is Thymosin Alpha-1 and is it FDA approved?

Thymosin Alpha-1 (thymalfasin, trade name Zadaxin) is a synthetic 28-amino acid peptide originally isolated from thymic tissue, studied primarily as an immune modulator. It is approved as a prescription drug in more than 35 countries for hepatitis B and C treatment. It is not approved by the U.S. FDA, and in 2023 the FDA specifically restricted its compounding. In the United States it is a research compound. Where approved internationally, it is a regulated pharmaceutical used under medical supervision.

What does the Thymosin Alpha-1 research actually show?

Based on articles retrieved from PubMed, the research record includes: (1) multiple published RCTs in chronic hepatitis B showing statistically significant HBV DNA clearance vs. controls; (2) Phase III hepatitis C data showing mixed results on sustained virologic response but reduced relapse in completers; (3) clinical sepsis studies showing reduced mortality and secondary infection rates; (4) mechanistic studies documenting TLR2/TLR9-driven dendritic cell activation and Th1 polarization; and (5) ongoing investigation in cancer adjuvant and infectious disease prevention contexts. This is a more robust human clinical data set than most research compounds in this category carry.

What is Thymosin Alpha-1’s WADA status?

Thymosin Alpha-1 is not individually listed by name in current WADA Prohibited List enumerations. However, the S0 category covers non-FDA-approved pharmacological substances, which may capture Tα1 in U.S.-adjacent anti-doping contexts. Athletes should consult the WADA Global DRO tool and their national anti-doping organization directly, this article does not constitute anti-doping guidance.

How does Thymosin Alpha-1 differ from TB-500 (Thymosin beta-4)?

They are unrelated despite the shared name. Thymosin Alpha-1 is a 28-aa thymic immune modulator (TLR/Th1 pathways; hepatitis and sepsis clinical trial record). TB-500 is a synthetic fragment of the 43-aa Thymosin beta-4, which acts primarily through G-actin sequestration and cell migration in tissue-repair contexts. The two peptides share historical thymus-extract origins but differ in sequence, structure, receptor biology, and clinical history. See the full TB-500 compound profile and the tissue repair and recovery cluster overview for comparison.

Research use only. Not intended for human use. Not FDA approved in the United States. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. The international drug approval status of thymalfasin (Zadaxin) is cited as a documented regulatory fact, not as an endorsement of any use of this compound outside licensed medical supervision. All citations link to primary sources, read them in full. Must be 21+.